Newland Pharmaceutical Co., Ltd. (SHE:301277)

China flag China · Delayed Price · Currency is CNY
12.31
-0.08 (-0.65%)
Mar 9, 2026, 4:00 PM EDT
16.29%
Market Cap 4.89B
Revenue (ttm) 670.43M
Net Income (ttm) 123.72M
Shares Out 392.08M
EPS (ttm) 0.32
PE Ratio 39.51
Forward PE n/a
Dividend 0.29 (2.32%)
Ex-Dividend Date Apr 16, 2025
Volume 2,139,740
Average Volume 2,198,315
Open 12.24
Previous Close 12.39
Day's Range 12.22 - 12.42
52-Week Range 10.41 - 18.38
Beta 0.39
RSI 46.39
Earnings Date Mar 20, 2026

About Newland Pharmaceutical

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, l... [Read more]

Sector Healthcare
Founded 2005
Employees 1,042
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301277
Full Company Profile

Financial Performance

In 2024, Newland Pharmaceutical's revenue was 726.44 million, an increase of 11.51% compared to the previous year's 651.44 million. Earnings were 173.63 million, an increase of 9.22%.

Financial Statements

News

There is no news available yet.